RT Journal Article
SR Electronic
T1 High excess mortality during the COVID-19 outbreak in Stockholm Region areas with young and socially vulnerable populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.07.20147983
DO 10.1101/2020.07.07.20147983
A1 Calderón-Larrañaga, Amaia
A1 Vetrano, Davide L
A1 Rizzuto, Debora
A1 Bellander, Tom
A1 Fratiglioni, Laura
A1 Dekhtyar, Serhiy
YR 2020
UL http://medrxiv.org/content/early/2020/07/08/2020.07.07.20147983.abstract
AB Background We aimed to describe the distribution of excess mortality (EM) during the first weeks of the COVID-19 outbreak in the Stockholm Region, Sweden, according to individual age and sex, and the sociodemographic contextMethods Weekly all-cause mortality data were obtained from Statistics Sweden for the period 01/01/2015 to 17/05/2020. EM during the first 20 weeks of 2020 was estimated by comparing observed mortality rates with expected mortality rates during the five previous years (N=2,379,792). EM variation by socioeconomic status (tertiles of income, education, Swedish-born, gainful employment) and age distribution (share of 70+ year-old persons) was explored based on Demographic Statistics Area (DeSO) data.Findings An EM was first detected during the week of March 23-29 2020. During the peaking week of the epidemic (6-12 April 2020), an EM of 160% was observed: 211% in 80+ year-old women; 179% in 80+ year-old men. During the same week, the highest EM was observed for DeSOs with lowest income (171%), lowest education (162%), lowest share of Swedish-born (178%), and lowest share of gainfully employed (174%). There was a 1.2 to 1.7-fold increase in EM between those areas with a higher vs. lower proportion of young people.Interpretation Living in areas with lower socioeconomic status and younger populations is linked to COVID-19 EM. These conditions might have facilitated the viral spread. Our findings add to the well-known biological vulnerability linked to increasing age, the relevance of the sociodemographic context when estimating the individual risk to COVID-19.Funding None.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approval was needed for the present study given the use of aggregate-level data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDara for this study were provided by Statistics Sweden, SCB (https://www.scb.se/en/)